Previous section Next section
HYPOGLYCEMIA
Body_ID: HC020026
Hypoglycemia (a low concentration of blood glucoseView drug information) is defined as a blood glucoseView drug information concentration below 2.5 mmol/L (45 mg/dL) (see Fig. 20.8). A decrease in plasma glucoseView drug information concentration stimulates the sympathetic nervous system. EpinephrineView drug information and glucagon are released, resulting in a stress response, the manifestations of which may include sweating, trembling, increased heart rate, and a feeling of hunger. If blood glucoseView drug information continues to fall, brain function is compromised owing to lack of glucoseView drug information (neuroglycopenia). The patient becomes confused and may lose consciousness. Profound hypoglycemia can be fatal.
Body_ID: P020027
page 278
0
page 279
Body_ID: P0279
Body_ID: P020029
Body_ID: F020006
Figure 20.6 Regulation of gluconeogenesis and glycolysis by phosphofructokinase (see Fig. 20.7). Glucagon regulates gluconeogenesis by controling the bifunctional enzyme complex that contains both phosphofructokinase-2 (PFK-2) and fructose 2,6-biphosphatase-2 (Fru-2,6-BPase-2) activity. This changes the concentration of fructose-2,6-biphosphate (Fru-2,6-BP), which in turn regulates the activity of 'mainline' enzymes: PFK-1 and Fru-2,6-BPase-1. See also Chapters 11 and 12.
GLYCOGEN STORAGE DISEASES
Body_ID: B020004
Glycogen is degraded in response to a falling blood glucoseView drug information concentration. A defect in the glycogenolytic pathway can lead to insufficient glucoseView drug information supply and may cause hypoglycemia. This happens in patients with inherited deficiencies of enzymes controling glycogen metabolism. Seven types of glycogen storage disease are known. They are very rare, but provide an excellent insight into human energy metabolism (see Chapter 12). The symptoms of glycogen storage diseases vary and depend on the site of the enzyme defect. For instance, type 1 glycogen storage disease (von Gierke's disease) is a deficiency of Glc-6-Pase, which leads to a fasting hypoglycemia unresponsive to epinephrineView drug information and glucagon. On the other hand, patients with type V disease (McArdle's disease), which is caused by muscle phosphorylase deficiency, do not experience hypoglycemia, but have a limited ability to perform strenuous exercise (see clinical box on p. 163).
Body_ID: PB20007
Hypoglycemia in healthy individuals is usually mild and may occur during exercise after a period of fasting, or as a result of drinking alcohol. Alcohol increases the intracellular NADH + H+/NAD+ ratio, which favors conversion of pyruvate to lactate and reduces the pool of pyruvate available for gluconeogenesis. Hypoglycemia may also be a feature of endocrine syndromes characterized by a low cortisol concentration caused by an insufficient amount of adrenocorticotrophic hormone (ACTH; see Chapter 37). Another endocrine cause of hypoglycemia is a rare insulin-secreting tumor of β-cells - insulinoma. Other causes are listed in Figure 20.9.
Body_ID: P020028
Integration link: Oral hypoglycemic drugsIntegration Link
Taken from Pharmacology 5E

Previous section
Bar end Bar end
Next section
Copyright © 2007 Elsevier Inc. All rights reserved. Read our Terms and Conditions of Use and our Privacy Policy.
For problems or suggestions concerning this service, please contact: studentconsult.help@elsevier.com